Japanese Patent Office Approves Inventiva's Patent For Use Of Lanifibranor In Treating Cirrhosis, Strengthening IP For MASH/NASH Indications; Patent Valid Until November 2039
Portfolio Pulse from Benzinga Newsdesk
The Japanese Patent Office has approved Inventiva's patent for the use of Lanifibranor in treating cirrhosis, which strengthens its intellectual property for MASH/NASH indications. The patent is valid until November 2039.
July 25, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The approval of Inventiva's patent in Japan may have a minor positive impact on the iShares MSCI Japan ETF (EWJ) as it reflects positively on the Japanese regulatory environment for biotech innovations.
While the news is directly related to Inventiva, it may have a minor positive impact on EWJ as it highlights the supportive regulatory environment in Japan for biotech innovations. However, the impact on EWJ is expected to be limited.
CONFIDENCE 70
IMPORTANCE 30
RELEVANCE 20
POSITIVE IMPACT
Inventiva has received approval from the Japanese Patent Office for its patent on Lanifibranor for treating cirrhosis, enhancing its IP for MASH/NASH indications until November 2039.
The approval of the patent in Japan extends the protection of Inventiva's drug Lanifibranor, which is significant for its market position in treating MASH/NASH. This could positively impact the stock price in the short term as it strengthens the company's IP portfolio.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100